Patients with Major Depressive disorder (MDD) have been shown to achieve remission within three months following treatment with SPL026 combined with supportive therapy in Small Pharma’s...
In a partnership that has been described as “an important step to reintroduce psychedelics into society”, Dimensions and the New Health Club are joining together to...
Study participants demonstrated a durable response at least six months, and in some cases a year or more, after their final MDMA-assisted therapy session during the...
A group of 13 individuals have become the first people to be licensed to facilitate psilocybin experiences in the United States outside of clinical trials in...
Enosis Therapeutics, OVID Clinics and the MIND Foundation for Psychedelic Research have joined together to implement the world’s first in-clinic application of Virtual Reality (VR) combined...
Justin Townsend, CEO of MycoMeditations, explores what to look for when evaluating a psychedelic retreat if you are considering attending – from what models to consider...
A new collaboration between Emyria and Australia’s specialist trauma service, the PAX Centre, is aiming to develop a scalable MDMA-assisted therapy model for patients with complex...
In this article, Nina Patrick, Ph.D.,
As psychedelic research increases, and a number of policy developments across the likes of the US, Canada and Australia are now enabling the delivery of psychedelic...
Tadeusz Hawrot, Founder and Executive Director of the Psychedelic Access and Research European Alliance (PAREA), speaks to Psychedelic Health about how the organisation plans to campaign...
